S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
NYSE:PKI

PerkinElmer Stock Forecast, Price & News

$127.53
-2.19 (-1.69 %)
(As of 03/2/2021 05:18 PM ET)
Add
Compare
Today's Range
$127.44
Now: $127.53
$130.82
50-Day Range
$125.97
MA: $144.85
$159.25
52-Week Range
$62.91
Now: $127.53
$162.70
Volume1.03 million shs
Average Volume1.04 million shs
Market Capitalization$14.28 billion
P/E Ratio34.65
Dividend Yield0.22%
Beta1.19
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
PerkinElmer logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
CUSIP71404610
Phone781-663-6900
Employees14,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$5.28 per share
Book Value$25.33 per share

Profitability

Net Income$227.56 million

Miscellaneous

Market Cap$14.28 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.91 out of 5 stars

Computer And Technology Sector

112th out of 1,528 stocks

Analytical Instruments Industry

2nd out of 29 stocks

Analyst Opinion: 1.3Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
$127.53
-2.19 (-1.69 %)
(As of 03/2/2021 05:18 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PerkinElmer (NYSE:PKI) Frequently Asked Questions

Is PerkinElmer a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PerkinElmer stock.
View analyst ratings for PerkinElmer
or view top-rated stocks.

What stocks does MarketBeat like better than PerkinElmer?

Wall Street analysts have given PerkinElmer a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PerkinElmer wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PerkinElmer?

PerkinElmer saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 2,640,000 shares, a decrease of 16.7% from the December 31st total of 3,170,000 shares. Based on an average daily volume of 938,200 shares, the short-interest ratio is currently 2.8 days.
View PerkinElmer's Short Interest
.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for PerkinElmer
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings results on Tuesday, February, 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.01 by $0.95. The medical research company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.22 billion. PerkinElmer had a trailing twelve-month return on equity of 21.57% and a net margin of 12.74%. The firm's revenue for the quarter was up 68.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.35 earnings per share.
View PerkinElmer's earnings history
.

How has PerkinElmer's stock price been impacted by Coronavirus?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PKI stock has increased by 75.1% and is now trading at $127.53.
View which stocks have been most impacted by COVID-19
.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, January 28th. Stockholders of record on Friday, April 16th will be given a dividend of $0.07 per share on Friday, May 7th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend is Thursday, April 15th.
View PerkinElmer's dividend history
.

Is PerkinElmer a good dividend stock?

PerkinElmer pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.22%. PerkinElmer does not yet have a strock track record of dividend growth. The dividend payout ratio of PerkinElmer is 6.83%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PerkinElmer will have a dividend payout ratio of 3.56% next year. This indicates that PerkinElmer will be able to sustain or increase its dividend.
View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY21 earnings guidance on Tuesday, February, 2nd. The company provided earnings per share guidance of at least $8.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.85. The company issued revenue guidance of at least $4.08 billion, compared to the consensus revenue estimate of $4.21 billion.

What price target have analysts set for PKI?

12 brokerages have issued 12 month price targets for PerkinElmer's shares. Their forecasts range from $45.00 to $193.00. On average, they expect PerkinElmer's stock price to reach $131.64 in the next twelve months. This suggests a possible upside of 3.2% from the stock's current price.
View analysts' price targets for PerkinElmer
or view top-rated stocks among Wall Street analysts.

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Dr. Prahlad R. Singh Ph.D., CEO, Pres & Director (Age 56, Pay $1.84M)
  • Mr. James M. Mock, Sr. VP & CFO (Age 44, Pay $901.44k)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 52, Pay $1.75M)
  • Mr. Robert Francis Friel, Advisor (Age 65, Pay $6.9M)
  • Mr. Tajinder Vohra, Sr. VP of Global Operations (Age 55)
  • Mr. Andrew Okun, VP & Chief Accounting Officer (Age 51)
  • Mr. Bryan Kipp, VP of Investor Relations
  • Mr. Daniel R. Tereau, Sr. VP of Strategy & Bus. Devel. (Age 53)
  • Ms. Miriame Victor, Sr. VP & Chief Commercial Officer
  • Mr. John L. Healy, VP, Associate Gen. Counsel & Assistant Sec.

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer CEO Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among PerkinElmer's employees.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), The Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Select Equity Group L.P. (9.22%), BlackRock Inc. (6.56%), Price T Rowe Associates Inc. MD (2.96%), Janus Henderson Group PLC (2.89%), King Luther Capital Management Corp (2.04%) and Primecap Management Co. CA (1.63%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James M Mock, Joel S Goldberg, Pascale Witz, Peter Barrett and Prahlad R Singh.
View institutional ownership trends for PerkinElmer
.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, Schroder Investment Management Group, Alta Capital Management LLC, Primecap Management Co. CA, Great Lakes Advisors LLC, Prudential PLC, and King Luther Capital Management Corp. Company insiders that have sold PerkinElmer company stock in the last year include Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Peter Barrett, and Prahlad R Singh.
View insider buying and selling activity for PerkinElmer
or view top insider-selling stocks.

Which institutional investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Norges Bank, Robeco Institutional Asset Management B.V., Ceredex Value Advisors LLC, Assenagon Asset Management S.A., Amundi Pioneer Asset Management Inc., Wells Fargo & Company MN, and BlackRock Inc..
View insider buying and selling activity for PerkinElmer
or or view top insider-buying stocks.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $127.53.

How much money does PerkinElmer make?

PerkinElmer has a market capitalization of $14.28 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis.

How many employees does PerkinElmer have?

PerkinElmer employs 14,000 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

Where are PerkinElmer's headquarters?

PerkinElmer is headquartered at 940 WINTER STREET, WALTHAM MA, 02451.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.